Evaluation of the pharmacokinetics and pharmacodynamics of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infections using data from two phase 2 clinical studies

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 9, 2014, Pages 5005-5015

  Okusanya, Olanrewaju O ^a   Bhavnani, Sujata M ^a   Hammel, Jeffrey P ^a   Forrest, Alan ^a   Bulik, Catharine C ^a   Ambrose, Paul G ^a   Gupta, Renu ^b  

^a INSTITUTE FOR CLINICAL PHARMACODYNAMICS   (United States)

^b Insmed Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; LIPOSOME; PLACEBO; ANTIINFECTIVE AGENT;

ADULT; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL LOAD; CHRONIC DISEASE; COLONY FORMING UNIT; COMPARTMENT MODEL; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSAGE FORM COMPARISON; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SPUTUM LEVEL; DRUG URINE LEVEL; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; KIDNEY CLEARANCE; LIPOSOMAL DELIVERY; LUNG FIBROSIS; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MEDICAL NEBULIZER; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; SPUTUM ANALYSIS; URINALYSIS; ADOLESCENT; AGED; CHILD; DRUG EFFECTS; INHALATIONAL DRUG ADMINISTRATION; LUNG; MICROBIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PROCEDURES; PSEUDOMONAS INFECTIONS; YOUNG ADULT;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; AGED; AMIKACIN; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; CHILD; CLINICAL TRIALS, PHASE II AS TOPIC; CYSTIC FIBROSIS; FEMALE; HUMANS; LIPOSOMES; LUNG; MALE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RESPIRATORY FUNCTION TESTS; YOUNG ADULT;

EID: 84906082955     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02421-13     Document Type: Article

References (17)

1. Gibson RL, Burns JL, Ramsey BW. 2003. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am. J. Respir. Crit. Care Med. 168:918-951. http://dx.doi.org/10.1164/rccm.200304-505SO. (Pubitemid 37267172)
2. Cystic Fibrosis Foundation. 2008. Patient registry: annual data report 2008. Cystic Fibrosis Foundation, Bethesda, MD.
3. Doring G, Conway SP, Heijerman HG, Hodson ME, Høiby N, Smyth A, Touw DJ. 2000. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur. Respir. J. 16:749-767. http://dx.doi.org/ 10.1034/j.1399-3003.2000.16d30.x.
4. Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL. 2002. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr. Pulmonol. 34:91-100. http://dx.doi.org/10.1002/ppul.10127. (Pubitemid 34809519)
5. Henry RL, Mellis CM, Petrovic L. 1992. Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Pediatr. Pulmonol. 12:158-161. http://dx.doi.org/10.1002/ppul.1950120306.
6. Novartis. 2013. Tobi (tobramycin inhalation solution). package insert. Novartis Pharmaceuticals Corporation, East Hanover, NJ. https://www.pharma.us. novartis.com/product/pi/pdf/tobi.pdf.
7. Gilead Sciences, Inc. 2012. Cayston (aztreonam for inhalation solution) product monograph. Gilead Sciences, Inc., Forrest City, CA.
8. Modi AC, Lim CS, Yu N, Geller D, Wagner MH, Quittner AL. 2006. A multi-method assessment of treatment adherence for children with cystic fibrosis. J. Cyst. Fibros. 5:177-185. http://dx.doi.org/10.1016/j.jcf.2006.03. 002. (Pubitemid 44063951)
9. Okusanya OO, Bhavnani SM, Hammel JP, Minic P, Dupont LJ, Forrest A, Mulder GJ, Mackinson C, Ambrose PG, Gupta R. 2009. Pharmacokinetic and pharmacodynamic evaluation of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infection. Antimicrob. Agents Chemother. 53:3847-3854. http://dx.doi.org/10.1128/AAC.00872-08.
10. Clancy JP, Dupont L, Konstan MW, Billings J, Fustik S, Goss CH, Lymp J, Minic P, Quittner AL, Rubenstein RC, Young KR, Saiman L, Burns JL, Govan JRW, Ramsey B, Gupta R, Arikace Study Group. 2013. Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection. Thorax 68:818-825. http://dx.doi.org/10.1136/thoraxjnl-2012-202230.
11. Bauer RJ. 2006. S-ADAPT/MCPEM User's Guide: software for pharmacokinetic, pharmacodynamic and population data analysis. Berkeley, CA.
12. Beal SL. 2001. Ways to fit a PK model with some data below the quantification limit. J. Pharmacokinet. Pharmacodyn. 28:481-504. http://dx.doi.org/10.1023/A:1012299115260. (Pubitemid 33151426)
13. Hollander M, Wolfe DA. 1973. Nonparametric statistical inference. John Wiley & Sons, New York, NY.
14. Konstan MW, Flume PA, Kappler M, Chiron R, Higgins M, Brockhaus F, Zhang J, Angyalosi G, He E, Gellar DE. 2011. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: the EAGER trial. J. Cyst. Fibros. 10:54-61. http://dx.doi.org/10.1016/j.jcf.2010.10.003.
15. Retsch-Bogart GA, Quittner AL, Gibson RL, Oermann CM, McCoy KS, Montgomery AB, Cooper PJ. 2009. Efficacy and safety of inhaled aztreonam lysine for airway Pseudomonas in cystic fibrosis. Chest 135:1223-1232. http://dx.doi.org/10.1378/chest.08-1421.
16. Assael BM, Pressler T, Bilton D, Fayon M, Fischer R, Chiron R, Larosa M, Knoop C, McElvaney N, Lewis SA, Bresnik M, Montgomery AB, Oermann CM, AZLI Active Comparator Study Group. 2013. Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: a comparative efficacy trial. J. Cyst. Fibros. 12:130-140. http://dx.doi.org/10.1016/j.jcf.2012.07.006.
17. Oermann CM, Retsch-Bogart GZ, Quittner AL, Gibson RL, McCoy KS, Montgomery AB, Cooper PJ. 2010. An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis. Pediatr. Pulmonol. 45:1121-1134. http://dx.doi.org/10.1002/ppul.21301.